Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Nicox SA is a France based ophthalmic corporation. It is focused on operating in the ophthalmic market through a diversified portfolio of ophthalmic products. The company’s pipeline features VESNEO for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; AC-170 for the treatment of ocular itching associated with allergic conjunctivitis; AzaSite for bacterial conjunctivitis; and BromSite for pain and inflammation after cataract surgery. The group operates internationally and is also focused on developing a pipeline of ophthalmology-focused candidates which utilize its proprietary nitric oxide-donating research platform.
Sophia Antipolis Cedex, 06560, France